×
About 2,138 results

ALLMedicine™ Primary Myelofibrosis Center

Research & Reviews  716 results

Optimizing PTCy Dose and Timing
https://clinicaltrials.gov/ct2/show/NCT03983850

Jun 24th, 2022 - Background: Post-transplantation cyclophosphamide (PTCy) reduces rates of severe acute and chronic graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (HCT) and safely facilitates human leukocyte antigen (HLA)-hapl...

A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously T...
https://clinicaltrials.gov/ct2/show/NCT03755518

Jun 23rd, 2022 - This is Single-Arm, Open-Label Efficacy and Safety Trial of Fedratinib in Subjects with DIPSS (Dynamic International Prognostic Scoring System)-Intermediate or High- Risk Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (post-PV M...

An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-e...
https://clinicaltrials.gov/ct2/show/NCT03952039

Jun 21st, 2022 - This Phase 3, multicenter, randomized, two-arm, open-label study will include subjects with intermediate or high-risk (as per the DIPSS score) primary myelofibrosis (PMF), postpolycythemia vera myelofibrosis (post-PV MF), or post-essential thrombo...

Extended Access of Momelotinib in Adults With Myelofibrosis
https://clinicaltrials.gov/ct2/show/NCT03441113

Jun 10th, 2022 - The primary objective of this study is to provide extended access and assess long-term safety of momelotinib (MMB) in participants with primary myelofibrosis (PMF) or post-polycythemia vera or post-essential thrombocythemia myelofibrosis (Post-PV/...

see more →

Guidelines  1 results

Guideline for the diagnosis and management of myelofibrosis.
https://doi.org/10.1111/j.1365-2141.2012.09179.x
British Journal of Haematology; Reilly JT, McMullin MF et. al.

Jun 2nd, 2012 - The guideline group regarding the diagnosis and management of myelofibrosis was selected to be representative of UK-based medical experts, together with a contribution from a single expert from the USA. MEDLINE and EMBASE were searched systematica...

see more →

Drugs  1 results see all →

Clinicaltrials.gov  72 results

Optimizing PTCy Dose and Timing
https://clinicaltrials.gov/ct2/show/NCT03983850

Jun 24th, 2022 - Background: Post-transplantation cyclophosphamide (PTCy) reduces rates of severe acute and chronic graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (HCT) and safely facilitates human leukocyte antigen (HLA)-hapl...

A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously T...
https://clinicaltrials.gov/ct2/show/NCT03755518

Jun 23rd, 2022 - This is Single-Arm, Open-Label Efficacy and Safety Trial of Fedratinib in Subjects with DIPSS (Dynamic International Prognostic Scoring System)-Intermediate or High- Risk Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (post-PV M...

An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-e...
https://clinicaltrials.gov/ct2/show/NCT03952039

Jun 21st, 2022 - This Phase 3, multicenter, randomized, two-arm, open-label study will include subjects with intermediate or high-risk (as per the DIPSS score) primary myelofibrosis (PMF), postpolycythemia vera myelofibrosis (post-PV MF), or post-essential thrombo...

Extended Access of Momelotinib in Adults With Myelofibrosis
https://clinicaltrials.gov/ct2/show/NCT03441113

Jun 10th, 2022 - The primary objective of this study is to provide extended access and assess long-term safety of momelotinib (MMB) in participants with primary myelofibrosis (PMF) or post-polycythemia vera or post-essential thrombocythemia myelofibrosis (Post-PV/...

Characteristics of Patients With Philadelphia Negative Myeloproliferative Neoplasms at Assiut University Hospital
https://clinicaltrials.gov/ct2/show/NCT05401864

Jun 8th, 2022 - Diagnosis of MPN according to the revised 2008 WHO criteria is based on a. combination of clinical, morphological, and molecular parameters ( Cardinal features of Philadelphia chromosome-negative MPN are increased red blood cell (RBC). production ...

see more →

News  64 results

Pacritinib Paves a “Unique Lane” of Treatment for Select Myelofibrosis
https://www.onclive.com/view/pacritinib-paves-a-unique-lane-of-treatment-for-select-myelofibrosis

Apr 5th, 2022 - Patients who develop post–essential thrombocythemia myelofibrosis (PET-MF) or post–polycythemia vera myelofibrosis (PPV-MF), which are associated with significant symptom burden and bone marrow failure, have limited therapies available for effecti...

Rapidly Enlarging Bullous Plaque
https://www.mdedge.com/dermatology/article/252463/dermatopathology/rapidly-enlarging-bullous-plaque
Marina Kristy Ibraheim, MD, Katherine Martin, MD et. al.

Mar 7th, 2022 - The Diagnosis: Bullous Pyoderma Gangrenosum A bone marrow biopsy revealed 60% myeloblasts, leading to a diagnosis of acute myeloid leukemia (AML). A biopsy obtained from the edge of the bullous plaque demonstrated a dense dermal neutrophilic infil.

FDA Extends Review Period for Pacritinib in Myelofibrosis With Severe Thrombocytopenia
https://www.onclive.com/view/fda-extends-review-period-for-pacritinib-for-myelofibrosis-with-severe-thrombocytopenia

Nov 30th, 2021 - The FDA has extended the review period for the new drug application (NDA) for pacritinib as a treatment for adult patients with intermediate- or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosi...

Treatment Strategies for Primary Myelofibrosis
https://www.onclive.com/view/treatment-strategies-for-primary-myelofibrosis

Sep 1st, 2021 - Srdan Verstovsek, MD, PhD: In 2019, fedratinib was approved and then incorporated into the national guidelines, these are the NCCN [National Comprehensive Cancer Network] guidelines. It was listed as a drug that can be used in the frontline settin...

Overview of Primary Myelofibrosis
https://www.onclive.com/view/overview-of-primary-myelofibrosis

Aug 30th, 2021 - Srdan Verstovsek, MD, PhD: Primary myelofibrosis has different signs and symptoms, but the 3 classic ones are, No. 1, bone marrow failure that represents itself with anemia in particular. No. 1 is the anemia. The second one is the symptomatic sple...

see more →

Patient Education  1 results see all →